OncoMatch/Clinical Trials/NCT05525273
Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma
Is NCT05525273 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Oral dabrafenib and trametinib for craniopharyngioma.
Treatment: Oral dabrafenib and trametinib — Subjects with papillary craniopharyngioma harboring a BRAF mutation will be treated with a BRAF + MEK inhibitor (dabrafenib + trametinib) after informed consent. Study participants will be administered oral dabrafenib and trametinib until maximal tumor volume reduction assessed by MRI. Progression free survival, cognition, ophthalmologic status, hypothalamic status and quality of life will be assessed 1 year after initiation of study treatment
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Biomarker criteria
Required: BRAF v600e
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: braf inhibitor
Cannot have received: mek inhibitor
Lab requirements
Blood counts
neutrophils > 1.5 x 10^9; platelets > 100 x 10^9
Kidney function
creatinine <1.5 x ULN or creatinine clearance <45 ml / min
Liver function
bilirubin <1.5 x ULN; ASAT (aspartate aminotransferase) / ALAT (alanine aminotransferase) <2.5 x ULN
neutrophils> 1.5 x 10^9 platelets> 100 x 10^9 creatinine <1.5 x ULN (upper limit of normal) or creatinine clearance <45 ml / min bilirubin <1.5 x ULN ASAT (aspartate aminotransferase) / ALAT (alanine aminotransferase) <2.5 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05525273 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior braf inhibitor, mek inhibitor disqualifies patients from enrollment.
Does this trial require BRAF?
Yes, BRAF v600e is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify